A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor

[1]  P. LoRusso,et al.  Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug–drug interactions , 2005, Cancer Chemotherapy and Pharmacology.

[2]  P. LoRusso,et al.  Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration , 2005, Cancer Chemotherapy and Pharmacology.

[3]  Hanlin Gao,et al.  DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS. , 2003, Molecular pharmacology.

[4]  R. Mohammad,et al.  2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. , 2002, Molecular cancer therapeutics.

[5]  S. Hazeldine,et al.  II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). , 2002, Journal of medicinal chemistry.

[6]  P. LoRusso,et al.  Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice , 2002, Investigational New Drugs.

[7]  Hong Lin,et al.  XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway , 2002, Cancer Chemotherapy and Pharmacology.

[8]  Jun Yu Li,et al.  The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  S. Hazeldine,et al.  Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). , 2001, Journal of medicinal chemistry.

[10]  G. Li,et al.  Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. , 2001, Biochemical and biophysical research communications.

[11]  Hanlin Gao,et al.  XK469, a selective topoisomerase IIbeta poison. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Trainor,et al.  Preclinical antitumor activity of XK469 (NSC 656889) , 1998, Investigational New Drugs.

[13]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[14]  M J Ratain,et al.  Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. , 1993, Journal of the National Cancer Institute.

[15]  E J Freireich,et al.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.

[16]  P. LoRusso,et al.  Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate , 2004, Investigational New Drugs.